In NAFLD, activation of AMPK in the liver inhibits the synthesis and oxidation of FFAs, leading to the reduction of ectopic lipid accumulation and improved insulin action [35]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.